Calistoga Pharamaceuticals, Inc. is the leader in developing innovative oral medicines targeting selected isoforms of the PI3 kinase pathway to improve the health of patients with cancer and inflammatory diseases.

PRESS RELEASES

Calistoga Pharmaceuticals Appoints Langdon L. Miller, M.D., Executive Vice President, Research & Development

29 July 2010 | View PDF |

Calistoga Pharmaceuticals Raises $40 Million in Series C Financing

30 June 2010 | View PDF |

Calistoga Pharmaceuticals Presents Preclinical and Clinical Data Supporting Benefit of First in Class, Novel Mechanism of CAL-101, an Oral Delta Isoform-Selective PI3 Kinase Inhibitor

14 June 2010 | View PDF |

Calistoga Pharmaceuticals' CAL-101, an Oral Delta Isoform-Selective PI3 Kinase Inhibitor, Demonstrates Clinical Benefit in Patients with Relapsed or Refractory Indolent Non Hodgkin's Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia

6 June 2010 | View PDF |

Calistoga Pharmaceuticals Announces Presentation on CAL-101 at American Society of Clinical Oncology (ASCO) Annual Meeting: Clinical Response Data in Patients with Hematologic Malignancies

21 May 2010 | View PDF |

Calistoga Pharmaceuticals Initiates Combination Trial of CAL-101 with Rituxan® and/or Treanda® in Patients with Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

7 April 2010 | View PDF |

Calistoga Pharmaceuticals' CAL-101, an Oral Delta Isoform-Selective PI3 Kinase Inhibitor, Demonstrates Clinical Benefit in Patients with Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia

8 December 2009 | View PDF |

Calistoga Pharmaceuticals Announces Two Oral Presentations on CAL-101 at 51st American Society of Hematology (ASH) Annual Meeting

1 December 2009 | View PDF |

Calistoga Pharmaceuticals Presents Preclinical Data on CAL-120 at The AACR-EORTC-NCI Molecular Targets & Cancer Therapeutics Conference

17 November 2009 | View PDF |

Calistoga Pharmaceuticals Presents Interim Clinical Efficacy Results from Ongoing Clinical Trial of CAL-101 at the International Workshop on Chronic Lymphocytic Leukemia

19 October 2009 | View PDF |

Calistoga Pharmaceuticals is pleased to have been selected to Fierce Biotech's Fierce 15 for 2009

1 July 2009 | FierceBiotech |

Calistoga Pharmaceuticals Reports Additional Clinical Responses in Ongoing Clinical Trial of CAL-101, an Isoform-Selective PI3 Kinase Inhibitor, Under Evaluation in Patients with Hematologic Malignancies

6 June 2009 | View PDF |

Calistoga Pharmaceuticals' CAL-101, an Oral Delta Isoform-Selective PI3 Kinase Inhibitor, Demonstrates Clinical Activity in Patients with Hematologic Cancers

30 May 2009 | View PDF |

Calistoga Pharmaceuticals Raises $30 Million in Series B Financing

5 May 2009 | View PDF |

Calistoga Pharmaceuticals Announces Presentations on CAL-101 and CAL-120 at the American Association for Cancer Research Annual Meeting

21 April 2009 | View PDF |

Calistoga Pharmaceuticals Announces Appointment of Clifford J. Stocks as Chief Business Officer

11 March 2009 | View PDF |

CAL-101, an Oral p110 (delta) Isoform-Selective PI3 Kinase Inhibitor, Demonstrates Preclinical Activity in Hematologic Cancer Cells

8 December 2008 | View PDF |

Calistoga Pharmaceuticals appoints Carol G. Gallagher, Pharm. D., Chief Executive Officer

8 October 2008 | View PDF |

Calistoga Pharmaceuticals Initiates First Oncology Clinical Trial Of Novel PI3K Delta Inhibitor, CAL-101

10 July 2008 | ClinicalTrials.gov |

Calistoga Pharmaceuticals initiates its First Clinical Study of Novel Oral PI3K Delta Compound, CAL-101.

10 March 2008 | View PDF |

Reuters - New target promises better asthma and allergy drugs.

14 February 2008 | www.reuters.com |

Calistoga Pharmaceuticals Appoints R. Lee Douglas to BOD

13 February 2008 | View PDF |

Calistoga Pharmaceuticals announces completion of its Series A Financing - Investors increased funding by 25% to total $26.2 Million

3 January 2008 | View PDF |

Calistoga Pharmaceuticals, a newly formed drug development company, announces its formation and completion of $21 million Series A Financing

5 March 2007 | View PDF |